Crinetics Pharmaceuticals (CRNX) Other Gross PP&E Adjustments (2017 - 2026)

Crinetics Pharmaceuticals has reported Other Gross PP&E Adjustments for 10 years, with the latest figure at -$17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 19.7% year-over-year to -$17.2 million; the trailing twelve-month figure through Mar 2026 stood at -$17.2 million (up 19.7% YoY), and the FY2025 full-year result was -$41.7 million, changed 0.32% from the prior year.
• Other Gross PP&E Adjustments for Q1 2026 stood at -$17.2 million, up from -$41.7 million in the prior quarter.
• The five-year high for Other Gross PP&E Adjustments was $6.6 million in Q2 2023, with the low at -$42.8 million in Q4 2023.
• Average Other Gross PP&E Adjustments over 5 years is -$17.0 million, with a median of -$19.7 million recorded in 2025.
• Year-over-year, Other Gross PP&E Adjustments surged 360.51% in 2022 and plunged 1967.97% in 2023.
• Tracing CRNX's Other Gross PP&E Adjustments over 5 years: stood at -$2.1 million in 2022, then sank by 1967.97% to -$42.8 million in 2023, then grew by 2.36% to -$41.8 million in 2024, then grew by 0.32% to -$41.7 million in 2025, then surged by 58.71% to -$17.2 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$17.2 million (Q1 2026), -$41.7 million (Q4 2025), and -$19.7 million (Q3 2025), per Business Quant data.

Peer Comparison